Which Cancer Patients Actually Respond to Metabolic Therapy?

By Editorial Team

Introduction: The Promise and the Gap

Metabolic therapy in oncology — encompassing ketogenic diets, caloric restriction, glucose-lowering drugs like metformin, and combinations thereof — has moved from fringe hypothesis to serious clinical inquiry over the past decade. Yet a fundamental question persists in both the research literature and the clinic: which patients actually respond?

The answer is neither simple nor universal. Response to metabolic interventions appears to depend on tumor genetics, metabolic phenotype, immune context, and patient physiology. Understanding these variables is no longer optional for clinicians or researchers seeking to apply these approaches responsibly.

This article reviews the current evidence on patient selection for metabolic therapy, identifies the biomarkers and tumor characteristics most associated with response, and highlights where the field still lacks clarity.

What Is Metabolic Therapy in Cancer?

Metabolic therapy refers to any intervention that targets the altered energy metabolism of cancer cells. The theoretical basis originates with Otto Warburg's 1924 observation that tumors preferentially ferment glucose to lactate even in the presence of oxygen — now known as the Warburg effect.

Common metabolic interventions include:

  • Ketogenic diet (KD): High-fat, very-low-carbohydrate diet that lowers blood glucose and raises ketone bodies. Healthy cells can use ketones; many cancer cells cannot efficiently.
  • Caloric restriction and fasting: Systemic reduction in insulin, glucose, and IGF-1.
  • Metformin and other biguanides: Inhibit mitochondrial Complex I, reducing oxidative phosphorylation and lowering circulating insulin.
  • 2-Deoxyglucose (2-DG): A glucose analogue that competitively inhibits glycolysis.
  • Hyperbaric oxygen therapy (HBOT): Used adjunctively to increase oxygen delivery, potentially impairing anaerobic metabolism.

These are increasingly used in combination — a framework some researchers call the "Press-Pulse" strategy — rather than as monotherapies.

Why Response Is Not Universal: The Metabolic Heterogeneity Problem

One of the most important findings in cancer metabolism research over the past decade is that tumors are metabolically heterogeneous — both between patients and within individual tumors.

While many tumors show strong Warburg physiology (glucose-dependent, lactate-exporting), others rely heavily on:

  • Oxidative phosphorylation (OXPHOS) — mitochondrially active and potentially ketone-capable
  • Fatty acid oxidation (FAO) — upregulated in some triple-negative breast cancers and therapy-resistant populations
  • Glutamine metabolism — particularly in pancreatic and lung adenocarcinomas
  • Lipid synthesis pathways — common in prostate and endometrial cancers

A tumor that relies on OXPHOS or glutamine, rather than aerobic glycolysis, may not respond — and could theoretically thrive — on a ketogenic diet that shifts systemic substrate availability toward fat and ketones.

This is why metabolic phenotyping of the tumor before intervention is now considered a prerequisite in serious clinical investigations.

Tumor Types with the Strongest Signal for Response

1. Glioblastoma Multiforme (GBM)

GBM is the most extensively studied cancer in metabolic oncology. Several features make it a compelling target:

  • High glucose dependency confirmed by PET imaging
  • Limited ability to metabolise ketone bodies due to deficient ketolytic enzyme expression (particularly OXCT1 and BDH1)
  • Brain parenchyma and healthy neurons adapt well to ketosis
  • Blood-brain barrier limits many conventional drug options, making dietary strategies attractive as adjuncts

Clinical trials including the ERGO study and multiple pilot trials have shown that a ketogenic diet combined with standard radiochemotherapy is feasible and associated with metabolic response in a subset of GBM patients. Responders tend to show measurable reductions in tumor glucose uptake on FDG-PET.

Key predictor of response: Low OXCT1 expression and high FDG uptake at baseline.

2. Pancreatic Ductal Adenocarcinoma (PDAC)

PDAC is one of the most treatment-resistant cancers. However, metabolic vulnerability is well-documented:

  • KRAS mutation (present in >90% of cases) drives constitutive glucose uptake via upregulation of GLUT1 and hexokinase II
  • Glutamine dependency is also high, complicating purely glucose-targeting strategies

Preclinical and early clinical data suggest caloric restriction mimetics and metformin may improve outcomes in diabetic PDAC patients, partly by reducing hyperinsulinemia. Patients with pre-existing type 2 diabetes who use metformin have consistently shown improved PDAC-specific survival in retrospective analyses.

Key predictor of response: KRAS G12D mutation, elevated fasting insulin, concurrent hyperglycemia.

3. Estrogen Receptor-Positive (ER+) Breast Cancer

Insulin and IGF-1 signalling are well-established drivers of ER+ breast cancer proliferation. Interventions that lower circulating insulin — including caloric restriction, intermittent fasting, and metformin — have shown:

  • Reduced Ki-67 proliferation index in neoadjuvant window studies
  • Improved outcomes in overweight/obese patients in several large retrospective analyses
  • Synergy with aromatase inhibitors (adipose tissue as a source of oestrogen is reduced with weight loss)

The CALERIE and DIRECT trials, while not oncology-specific, demonstrated that sustained caloric restriction produces the metabolic changes (lower insulin, lower IGF-1, reduced adipokines) hypothesised to reduce ER+ recurrence risk.

Key predictor of response: High BMI, elevated fasting insulin, high circulating IGF-1, ER+/HER2- subtype.

4. Prostate Cancer (Castration-Sensitive Phase)

Prostate cancer in its early hormone-sensitive phase exhibits significant insulin-sensitivity and responds to androgen signalling. Hyperinsulinemia accelerates progression. Intermittent fasting and low-glycaemic diets have been associated with:

  • Slower PSA doubling time in observational studies
  • Improved testosterone and metabolic profiles during active surveillance

Key predictor of response: Elevated BMI, metabolic syndrome, early-stage (active surveillance or post-primary treatment).

5. Certain Brain Metastases

Brain metastases from lung, breast, and melanoma primaries often show high FDG-PET avidity and reduced mitochondrial adaptation capacity. The sanctuary-site nature of the brain (limiting systemic drug penetration) makes metabolic co-interventions particularly interesting in this setting.

Patients Who Are Less Likely to Respond

Understanding non-responder profiles is equally important.

OXPHOS-Dominant Tumors

Cancers that are metabolically flexible or primarily OXPHOS-dependent include some:

  • Lymphomas (particularly follicular lymphoma)
  • Melanomas with high mitochondrial activity
  • Therapy-resistant clones following prior treatment

These tumors may adapt readily to ketone bodies as a fuel source, potentially negating the therapeutic effect of glucose restriction.

Cachexia-Prone Patients

Patients with significant cancer-related cachexia are poor candidates for caloric restriction approaches. Further energy deficit in this population accelerates muscle wasting, impairs immune function, and worsens quality of life without therapeutic benefit to the tumor.

Clinical rule: Metabolic restriction strategies should not be applied to patients with >5% unintentional weight loss over 6 months without aggressive nutritional support.

Patients on Gluconeogenic-Dependent Medications

Certain medications (particularly corticosteroids, commonly used in GBM management) significantly impair the ability to achieve therapeutic ketosis. Corticosteroids raise blood glucose via gluconeogenesis, counteracting ketogenic diets. These patients may require dexamethasone dose optimisation before metabolic strategies are attempted.

The Role of Biomarkers in Patient Selection

Blood Glucose and Insulin

Baseline fasting glucose and insulin levels are the most accessible surrogate markers for metabolic vulnerability. Patients with hyperinsulinemia are more likely to respond to insulin-lowering interventions. The HOMA-IR index (Homeostatic Model Assessment of Insulin Resistance) provides a simple calculation.

FDG-PET Standardised Uptake Value (SUV)

High FDG-PET SUVmax at baseline is a practical indicator of tumour glycolytic dependency. Tumours with SUVmax >10 are generally considered highly glycolytic and more likely to respond to glucose-targeting strategies.

Circulating Tumour DNA (ctDNA) and Metabolic Gene Panels

Emerging research is exploring whether specific somatic mutations predict metabolic phenotype:

  • PIK3CA mutations drive mTOR signalling and insulin dependency
  • PTEN loss heightens glucose uptake
  • KRAS mutations upregulate glycolytic enzyme expression
  • IDH1/2 mutations (in glioma) profoundly alter cellular metabolism toward 2-HG production, creating a distinct but targetable metabolic vulnerability

Ketone Body Levels During Intervention

In patients undergoing a ketogenic diet, failure to achieve blood beta-hydroxybutyrate (BHB) levels of ≥1.0 mmol/L is associated with non-response. Metabolic monitoring during intervention is therefore essential — dietary compliance alone is insufficient.

Practical Framework: A Patient Selection Algorithm

Clinicians considering metabolic therapy as an adjunct should evaluate patients across four dimensions:

1. Tumor metabolic phenotype

  • FDG-PET avidity
  • Known glycolytic driver mutations (KRAS, PIK3CA, PTEN loss)
  • Absence of documented OXPHOS dependence

2. Systemic metabolic state

  • Fasting glucose, insulin, HOMA-IR
  • BMI and body composition (adequate lean mass)
  • Absence of active cachexia

3. Treatment context

  • Corticosteroid use (impairs ketosis)
  • Concurrent chemotherapy (some regimens impair mitochondrial function)
  • Line of therapy (metabolic interventions may be more appropriate in maintenance or earlier disease)

4. Patient capacity and adherence

  • Dietary flexibility and cooking capacity
  • Willingness to undergo metabolic monitoring
  • Psychosocial support

Current Clinical Trials to Watch

Several ongoing and recently completed trials are generating high-quality data on responder identification:

  • NCT03805443 (KETOCOMP): Ketogenic diet plus standard therapy in GBM
  • NCT04199143: Intermittent fasting in early breast cancer (neoadjuvant window)
  • NCT03869193: Metformin plus chemotherapy in PDAC
  • MAST trial (UK): Metabolic adjunct strategies across solid tumours

These trials are incorporating prospective biomarker collection — a critical step toward personalized metabolic oncology.

Conclusion: Toward Precision Metabolic Oncology

The question is no longer whether metabolic therapy can affect cancer — the preclinical and early clinical evidence is sufficient to establish plausibility. The urgent question is who to treat, with what, and when.

The most consistent responders share several features: high tumour glycolytic dependency (confirmed by FDG-PET), glycolytic driver mutations, systemic hyperinsulinemia, and adequate baseline nutritional status. GBM, ER+ breast cancer, PDAC, and insulin-driven prostate cancer represent the highest-yield tumor types based on current evidence.

As ctDNA testing and metabolic profiling become more accessible, patient selection will move from clinical heuristics to precision molecular criteria. For now, the responsible application of metabolic therapy requires careful patient phenotyping, rigorous monitoring, and integration within — not replacement of — established oncological care.

This article is intended for healthcare professionals and informed patients. It does not constitute individual medical advice. Always consult a qualified oncologist before initiating any dietary or metabolic intervention.

Related:

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more